Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States

Abstract

The United States spends more for healthcare than any other country in the world. With the rising prevalence of both Crohn's disease and ulcerative colitis, inflammatory bowel disease (IBD) represents the leading chronic gastrointestinal disease with increasing healthcare expenditures in the US. IBD costs have shifted from inpatient to outpatient care since the introduction of biologic therapies as the standard of care. Gastroenterologists need to be aware of the national cost burden of IBD and clinical practices that optimize cost-efficiency. This investigation offers a systematic review of the economics of IBD and evidence-based strategies for cost-effective management.

An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013

“…In recent years, health care expenditures have shifted from the inpatient setting to the prescription setting due to the improvements associated with the introduction of biologics into standard of care for Crohn's disease. 23 This study found that prescription expenditure was a large proportion of the total expenditures for Crohn's disease (36%) followed by inpatient (25%), and outpatient (9%) expenditures. In contrast, Park and colleagues reported that inpatient expenditures represented a large proportion of total expenditures (36%) compared to prescriptions (8%) using MEPS data spanning from 1996 to 2011.…”

“…6 This appears reasonable given that costs may have shifted from inpatient to prescription expenditures due to the introduction of biologics in recent years. 23,24 The current study used MEPS data from the most recent 11 years to capture recent changes in prescribing practices. Hence, our prescription expenditure estimates were larger compared to those reported using older MEPS data.…”

Emerging biologics in inflammatory bowel disease

“…The current use of biologics is limited by their cost [37], and public health insurance coverage varies from country to country. In some countries, patients are required to pay for biologic therapy, and this is reflected in lower uptake of biologic therapy in these countries [38].…”

PWE-103 Terminal Ileitis At Endoscopy In Clinical Practice: Is It Always Due To Crohn’s Disease?

“…1 IBD Standards (Revised 2013) recommend telephone advice for patients with regards to symptoms and medication management. This report attempts to quantify the net financial impact of this service at our hospital since it was introduced in August 2013.…”